Keytruda Biosimilar FDA Review: FYB206 BLA Accepted
FDA has accepted the Zydus and Formycon FYB206 BLA for review, the first publicly announced Keytruda biosimilar filing. Decision possible in Q3 2027.
FILKRI Biosimilar US Launch: Accord Adds Short-Acting G-CSF
FILKRI biosimilar US launch: Accord BioPharma debuts filgrastim-laha, a Neupogen biosimilar, in two prefilled syringe sizes with permanent Q-code Q5172.